Pharma turns away from Germany

Several German and foreign pharma companies are announcing they will cut R&D spending or move R&D units out of Germany in response to mandatory price reductions the German government wants to introduce as part of a reform of the German statutory healthcare system.

In August, the German government and the leading opposition party, the Christian Democratic Union, agreed on a draft healthcare reform bill. The bill

Read the full 653 word article

How to gain access

Continue reading with a
two-week free trial.